CONSULTING AGREEMENT This CONSULTING AGREEMENT (the "Agreement") is entered into as of October 10, 1997, by and between BIOSPECIFICS TECHNOLGIES CORP., a Delaware corporation (the "Company"), and STEPHEN A. VOGEL, whose principal office is located at...Consulting Agreement • May 7th, 1998 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
AGREEMENT ---------Stock Pledge Agreement • May 17th, 2001 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
BIOSPECIFICS TECHNOLOGIES CORP. and OTC CORPORATE TRANSFER SERVICE COMPANY Rights AgentRights Agreement • May 30th, 2002 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
EXHIBIT 10.13 RECOURSE SECURED DEMAND NOTE ----------------------------Biospecifics Technologies Corp • May 17th, 2001 • Pharmaceutical preparations • New York
RECITALSSecurities Purchase Agreement • June 20th, 2003 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
EXHIBIT 10.20 NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOT HAVE BEEN REGISTERED WITH THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE...Biospecifics Technologies Corp • June 20th, 2003 • Pharmaceutical preparations
AGREEMENT AND PLAN OF MERGER BY AND AMONG ENDO INTERNATIONAL PLC, BETA ACQUISITION CORP. AND BIOSPECIFICS TECHNOLOGIES CORP. DATED AS OF OCTOBER 19, 2020Agreement and Plan of Merger • October 19th, 2020 • Biospecifics Technologies Corp • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of October 19, 2020 by and among Endo International plc, a public limited company incorporated in Ireland (“Parent”), Beta Acquisition Corp., a Delaware corporation and a wholly-owned Subsidiary of Parent (“Merger Sub”), and BioSpecifics Technologies Corp., a Delaware corporation (the “Company”).
DEVELOPMENT AND LICENSE AGREEMENT dated as of June 3, 2004 BY AND BETWEEN BIOSPECIFICS TECHNOLOGIES CORP. (a Delaware corporation) AND AUXILIUM PHARMACEUTICALS, INC. (A DELAWARE CORPORATION)Development and License Agreement • November 22nd, 2004 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
COMMERCIAL LEASE AGREEMENT THIS LEASE AGREEMENT is made and entered into this 30th day of January, 1998, by and between Wilbur St. Corp. (hereinafter referred to as ----------------- "Landlord"), and Advance Biofactures Corp. (hereinafter referred to...Commercial Lease Agreement • May 7th, 1998 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
BIOSPECIFICS TECHNOLOGIES CORP. Non-Employee Director Change of Control AgreementBiospecifics Technologies Corp • March 14th, 2016 • Pharmaceutical preparations • New York
This Non-Employee Director Change of Control Agreement, effective as of April 22, 2015, is entered into by and between BioSpecifics Technologies Corp., a Delaware corporation (the “Company”), with its principal offices located at 35 Wilbur Street, Lynbrook, NY 11563, and Dr. Jyrki Mattila (the “Director”).
BIOSPECIFICS TECHNOLOGIES CORP. Common Stock ($0.001 par value per share) AT- THE-MARKET EQUITY OFFERING SALES AGREEMENTTerms Agreement • August 31st, 2020 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
EXHIBIT 10.22 INVESTOR RIGHTS AGREEMENT This Agreement is made as of June 19, 2003, by and between BIOSPECIFICS TECHNOLOGIES CORP., a Delaware corporation (the "Company"), and BIO PARTNERS LP, a Delaware limited partnership (the "Investor"). NOW,...Investor Rights Agreement • June 20th, 2003 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
BIOSPECIFICS TECHNOLOGIES CORP. CONFIDENTIALITY AND INVENTIONS ASSIGNMENT AGREEMENTConfidentiality and Inventions Assignment Agreement • May 11th, 2020 • Biospecifics Technologies Corp • Pharmaceutical preparations • Delaware
In consideration and as a condition of my employment, or continued employment, by BioSpecifics Technologies Corp., a Delaware corporation (the “Company”), and the compensation now and hereafter paid to me, I hereby agree as follows:
LEASE AGREEMENTLease Agreement • March 16th, 2020 • Biospecifics Technologies Corp • Pharmaceutical preparations
Business machines and mechanical equipment belonging to Tenant, which cause noise or vibration that may be transmitted to the structure of the Building or to any space therein to such a degree as to be objectionable to Landlord or to any tenants in the Building, shall be placed and maintained by Tenant, at Tenant’s expense, on vibration eliminators or other devices sufficient to eliminate noise or vibration. The persons employed to move such equipment in or out of the Building must be acceptable to Landlord in Landlord’s reasonable discretion.
BIOSPECIFICS TECHNOLOGIES CORP. Non-Employee Director Change of Control AgreementControl Agreement • September 26th, 2007 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
This Non-Employee Director Change of Control Agreement, effective as of June 18, 2007 is entered into by and between BioSpecifics Technologies Corp., a Delaware corporation (the “Company”), with its principal offices located at 35 Wilbur Street, Lynbrook, NY 11563, and Michael Schamroth (the “Director”).
WITNESSETH:Regulatory Compliance Agreement • March 3rd, 2000 • Biospecifics Technologies Corp • Pharmaceutical preparations
AMENDMENT NO. 1 TO RIGHTS AGREEMENTRights Agreement • October 19th, 2020 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
This AMENDMENT NO. 1 TO RIGHTS AGREEMENT, dated as of October 19, 2020 (this “Amendment”), is made and entered into by and between BioSpecifics Technologies Corp., a Delaware corporation (the “Company”), and Worldwide Stock Transfer, LLC, as Rights Agent (the “Rights Agent”). Except as otherwise provided herein, capitalized terms used but not otherwise defined in this Amendment shall have the meanings ascribed to such terms in the Rights Agreement (as defined below).
BIOSPECIFICS TECHNOLOGIES CORP. Non-Employee Director Change of Control AgreementBiospecifics Technologies Corp • June 22nd, 2007 • Pharmaceutical preparations • New York
This Non-Employee Director Change of Control Agreement, effective as of June ___, 2007 is entered into by and between BioSpecifics Technologies Corp., a Delaware corporation (the “Company”), with its principal offices located at 35 Wilbur Street, Lynbrook, NY 11563, and ___________ (the “Director”).
WITNESSETH:Allocation of Responsibilities Agreement • March 3rd, 2000 • Biospecifics Technologies Corp • Pharmaceutical preparations
AMENDMENTBiospecifics Technologies Corp • January 12th, 2007 • Pharmaceutical preparations
This Amendment is made as of January 8, 2007 by and among DFB Biotech, Inc. a Delaware corporation (“Buyer”), and BioSpecifics Technologies Corp., a Delaware corporation (“BTC”), and its wholly-owned subsidiary Advance Biofactures Corporation, a New York corporation (“ABC”) (BTC and ABC each being hereinafter individually, and collectively where applicable, referred to as “Seller”). (Buyer and Seller are at times referred to herein collectively as the “Parties.”)
SECOND AMENDMENT TO SECOND AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • February 28th, 2019 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
This SECOND AMENDMENT TO SECOND AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT dated February 26, 2019, with an effective date as of January 1, 2019 (the “Second Amendment Effective Date”), is by and between BioSpecifics Technologies Corp., a Delaware corporation (“BTC”), and Endo Global Ventures, a Bermuda unlimited liability company (“Endo”). BTC and Endo shall sometimes be referred to herein collectively as “Parties.”
FIFTH AMENDMENT TO RIGHTS AGREEMENTRights Agreement • April 2nd, 2019 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
This FIFTH AMENDMENT (this “Amendment”), dated as of May 11, 2018, to the RIGHTS AGREEMENT, dated as of May 14, 2002, as amended on June 19, 2003, and as further amended on of February 3, 2011, March 5, 2014 and May 27, 2016 (the “Rights Agreement”), between BioSpecifics Technologies Corp., a Delaware corporation (the “Company”), and Worldwide Stock Transfer, LLC (as successor in interest to OTC Corporate Transfer Service Company) as Rights Agent (the “Rights Agent”).
RECOURSE SECURED PROMISSORY NOTE --------------------------------Recourse Secured • May 15th, 2000 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
PLEDGE AGREEMENTPledge Agreement • March 2nd, 2007 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
This PLEDGE AGREEMENT (this “Agreement”), effective as of the 1st day of January 2007 by and between THE S.J. WEGMAN COMPANY (the “Pledgor”) and BIOSPECIFICS TECHNOLOGIES CORP., a Delaware corporation (the “Secured Party”).
FOURTH AMENDMENT TO RIGHTS AGREEMENTRights Agreement • April 2nd, 2019 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
This FOURTH AMENDMENT (this “Amendment”), dated as of May 27, 2016, to the RIGHTS AGREEMENT, dated as of May 14, 2002, as amended on June 19, 2003, and as further amended on of February 3, 2011 and March 5, 2014 (the “Rights Agreement”), between BioSpecifics Technologies Corp., a Delaware corporation (the “Company”), and Worldwide Stock Transfer, LLC (as successor in interest to OTC Corporate Transfer Service Company) as Rights Agent (the “Rights Agent”).
BIOSPECIFICS TECHNOLOGIES CORP. RESTRICTED STOCK UNIT AWARD AGREEMENTRestricted Stock Unit Award Agreement • August 9th, 2019 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
This RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Award Agreement”), dated as of July 1, 2019 (the “Date of Grant”), is delivered by BioSpecifics Technologies Corp. (the “Company”) to Pat Caldwell, an individual, with a primary address at ____________ (the “Participant”).
BIOSPECIFICS TECHNOLOGIES CORP. DIRECTOR RESTRICTED STOCK UNIT AWARD AGREEMENTIncentive Compensation Plan • August 9th, 2019 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
This RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Award Agreement”), dated as of ________ (the “Date of Grant”), is delivered by BioSpecifics Technologies Corp. (the “Company”) to __________ (the “Participant”).
LEASE TERMINATION AGREEMENTLease Termination Agreement • March 7th, 2014 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
THIS AGREEMENT (this “Agreement”) is made as of the 21st day of November 2013 (the “Termination Date”) by and among WILBUR ST. CORP., a New York corporation (“Landlord”), and ADVANCE BIOFACTURES CORP., a New York corporation, and BIOSPECIFICS TECHNOLOGIES CORP., a Delaware corporation ( collectively, “Tenant”).
BioSpecifics Technologies Corp. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 8th, 2008 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
This Executive Employment Agreement (the “Agreement”) is entered into as of August 5, 2008 (the “Effective Date”) by and between BioSpecifics Technologies Corp. (the “Company”), and Thomas L. Wegman (“Executive”). This Agreement incorporates and supersedes the Change of Control Agreement entered into on June 18, 2007 between the Company and Executive. The Change of Control Agreement is no longer effective.
August 6, 2020 BY EMAIL AND OVERNIGHT MAIL Patrick C. Hutchison Dear Pat:Letter Agreement • August 10th, 2020 • Biospecifics Technologies Corp • Pharmaceutical preparations
This letter agreement (the “Amendment”) hereby amends your employment offer letter from BioSpecifics Technologies Corporation (“BSTC” or the “Company”) dated December 17, 2019 and executed by you on December 20, 2019 (the “Offer Letter”), solely as set forth below. In all other respects, the Offer Letter shall remain in full force and effect.
CONSULTING AGREEMENTConsulting Agreement • April 27th, 2012 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
THIS CONSULTING AGREEMENT (this “Agreement”), is made effective as of July 1, 2012 (“Effective Date”), by and between BioSpecifics Technologies Corp. (the “Company”), a Delaware corporation, Dr. Matthew Geller, an individual (“Dr. Geller”), and Geller Biopharm Inc., a New York corporation (“Consultant”), of which Dr. Geller is President.
Patrick M. Caldwell Amended and Restated Indemnification AgreementIndemnification Agreement • April 2nd, 2019 • Biospecifics Technologies Corp • Pharmaceutical preparations
In connection with the engagement of Patrick M. Caldwell ("PMC") to advise and assist the undersigned (together with its affiliates and subsidiaries, referred to as the "Company") with the matters set forth in the oral agreement between the Company and PMC (the "Agreement"), in the event that PMC becomes involved in any capacity in any claim, suit, action, proceeding, investigation or inquiry (including, without limitation, any stockholder or derivative action or arbitration proceeding) (collectively, a "Proceeding") in connection with any matter in any way relating to or referred to in the Agreement or arising out of the matters contemplated by the Agreement, including, without limitation, related services and activities prior to the date of the Agreement, the Company agrees to indemnify, defend and hold PMC harmless to the fullest extent permitted by law, from and against any losses, claims, damages, liabilities and expenses in connection with any matter in any way relating to or ref
DUPUYTREN’S DISEASE LICENSE AGREEMENTDupuytren’s Disease License Agreement • November 28th, 2006 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
This DUPUYTREN’S DISEASE LICENSE AGREEMENT (the “Agreement”), effective as of November 21, 2006 (the “Effective Date”), is entered into by and between BioSpecifics Technologies Corp., a corporation organized and existing under the laws of Delaware (“BTC”), and the Research Foundation of the State University of New York for and on behalf of Stony Brook University, a nonprofit, educational corporation organized and existing under the laws of New York (the “Research Foundation”). BTC and the Research Foundation shall sometimes be referred to herein individually as a “Party” and collectively as “Parties.”
ContractBiospecifics Technologies Corp • November 9th, 2018 • Pharmaceutical preparations
Re: Lease dated November 21, 2013 between 35 Wilbur Street Assoc., LLC and Advance Biofactures Corp., premises; 35 Wilbur Street, Lynbrook, NY 11563.
CONSULTING AGREEMENT Effective Date: April 1, 2019Consulting Agreement • April 2nd, 2019 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
THIS CONSULTING AGREEMENT (this “Agreement”), is entered into by and between BioSpecifics Technologies Corporation, a Delaware corporation (“BSTC” or the “Company”), and Pat Caldwell, an individual, with a primary address at 13485 Harding Avenue, San Martin, California 95046 (“Consultant”), as of the date set forth above (the “Effective Date”). BSTC and Consultant may each be referred to as a “Party” or together, the “Parties”.
